PRESS CENTER

2022-04-19

Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using Lonza’s GS Xceed® Gene Expression System

Luzhu Biotech entered a licensing agreement to use Lonza’s GS Xceed® Gene Expression System with GS piggyBac® transposon technology....

| More

2021-08-30

Luzhu Biotech completed Series B financing of CNY 350 million


On August 30, 2021, Beijing Luzhu Biotechnology Co., Ltd. announced the completion of Series B financing of CNY 350 million....

| More

2021-08-03

Luzhu Biotech obtained clinical trial approval for "Recombinant Herpes Zoster Vaccine (CHO cells)"

On August 3, 2021, Luzhu Biotech obtained clinical trial approval letter for "Recombinant Herpes Zoster Vaccine (CHO cells)" (Approval number: 2021LP01212)....

| More

ABOUT LUZHUPRODUCTSINVESTOR PRESS CENTERCONTACT US
COMPANY PROFILEPRODUCTS IN R&DNEWS
COMPANY MILESTONESIMMUNOREAGENT
HONOUROUT-LICENSED PRODUCTS
INTELLECTUAL PROPERTY
ABOUT LUZHU
COMPANY PROFILECOMPANY MILESTONESHONOURINTELLECTUAL PROPERTY
PRODUCTS
PRODUCTS IN R&DIMMUNOREAGENTOUT-LICENSED PRODUCTS
INVESTOR
PRESS CENTER
NEWS
CONTACT US
Copyright © 2022 Beijing Luzhu Biotechnology Co., Ltd. All Rights Reserved.
京ICP备 10053635号-1
京公安网备 11011202001190号